Systematic review and meta-analysis evaluates trilaciclib for chemotherapy-induced myelosuppression in solid tumors.

This systematic review and meta-analysis synthesized evidence regarding trilaciclib for chemotherapy-induced myelosuppression in solid-tumor patients receiving chemotherapy. The review included data from 726 patients across multiple studies with short follow-up in some instances. Setting details were not reported in the source material.

Key findings indicated a significant reduction in the incidence of severe neutropenia and febrile neutropenia. The duration of severe neutropenia was shortened, and the need for erythropoiesis-stimulating agents, granulocyte colony-stimulating factor, and red-blood-cell transfusions decreased. Anemia rates also decreased without increased risks of nausea, vomiting, or fatigue. Progression-free survival was significantly prolonged, though overall survival remained unchanged. Primary outcome data were not reported in the source material. Secondary outcomes included these hematologic parameters and survival metrics.

Authors note limitations including a small number of randomized controlled trials, heterogeneous chemotherapy regimens, and potential publication bias. Short follow-up in some studies may limit long-term safety assessments. Serious adverse events and discontinuations were not reported in the source data. Safety tolerability was not reported. The certainty of evidence was not reported. Funding sources were not reported. These limitations affect the strength of the conclusions. While the data can guide clinical use, further well-designed studies are warranted to consolidate its efficacy and safety profile.